Kathleen Van Dyk1, Xingtao Zhou2, Brent J Small3, Jaeil Ahn4, Wanting Zhai4, Tim Ahles5, Deena Graham6, Paul B Jacobsen7, Heather Jim8, Brenna C McDonald9, Kelly Nudelman Holohan10, Sunita K Patel11, G William Rebeck12, James C Root5,13, Andrew J Saykin14, Harvey Jay Cohen15, Jeanne S Mandelblatt16, Judith E Carroll1,17. 1. UCLA Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, David Geffen School of Medicine, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. 2. Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. 3. School of Aging Studies, University of South Florida, and Senior Member, Health Outcome and Behavior Program and Biostatistics Resource Core, H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL, USA. 4. Department of Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. 5. Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 6. John Theurer Cancer Center, Hackensack, NJ, USA. 7. Division of Cancer Control and Population Sciences, Healthcare Delivery Research Program, National Cancer Institute, Bethesda, MD, USA. 8. Department of Health Outcomes and Behavior, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA. 9. Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA. 10. Department of Medical and Molecular Genetics, Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA. 11. Departments of Population Sciences and Supportive Care Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 12. Department of Neurosciences, Georgetown University School of Medicine, Georgetown University, Washington, DC, USA. 13. Departments of Psychiatry and Anesthesiology, Weill Medical College of Cornell University, New York, NY, USA. 14. Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana Alzheimer's Disease Research Center, and the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA. 15. Center for the Study of Aging and Human Development, Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA. 16. Department of Oncology, Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. 17. Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA, USA.
Abstract
Background: Cancer-related cognitive decline (CRCD) has been linked to apolipoprotein E (APOE) gene ε4 polymorphisms. APOE ε4 polymorphisms are also the strongest genetic risk for late-onset Alzheimer disease (AD), whereas ε2 polymorphisms protect against AD. However, the effects of ε2 polymorphisms on CRCD have not been evaluated. Methods: We evaluated nonmetastatic breast cancer survivors (n = 427) and matched noncancer controls (n = 407) ages 60-98 years assessed presystemic therapy from August 2010 to December 2017 with annual follow-up to 24 months. Neuropsychological assessment measured attention, processing speed, executive function, and learning and memory. Linear mixed-effects models tested the effects of having an ε2 allele (vs none) on longitudinal cognitive domain z scores by treatment group (chemotherapy with or without hormonal therapy, hormonal therapy, and control) controlling for covariates; participants with ε2/ε4 genotype were excluded. Sensitivity analyses examined effects of other covariates and any ε4 positivity. Results: There was an interaction with genotype for attention, processing speed, and executive functioning domain scores (Beta = 0.32, 95% confidence interval = 0.00 to 0.65); the chemotherapy group with an ε2 allele had higher scores at baseline and maintained higher scores over time compared with those without an ε2 allele, and this protective effect was not seen for other groups. There was no effect of ε2 on learning and memory domain scores. Conclusions: APOE ε2 polymorphisms may protect against CRCD in older breast cancer survivors receiving chemotherapy. With replication, this information could be useful for survivorship care and informing future studies of possible links to AD and defining mechanisms of protection.
Background: Cancer-related cognitive decline (CRCD) has been linked to apolipoprotein E (APOE) gene ε4 polymorphisms. APOE ε4 polymorphisms are also the strongest genetic risk for late-onset Alzheimer disease (AD), whereas ε2 polymorphisms protect against AD. However, the effects of ε2 polymorphisms on CRCD have not been evaluated. Methods: We evaluated nonmetastatic breast cancer survivors (n = 427) and matched noncancer controls (n = 407) ages 60-98 years assessed presystemic therapy from August 2010 to December 2017 with annual follow-up to 24 months. Neuropsychological assessment measured attention, processing speed, executive function, and learning and memory. Linear mixed-effects models tested the effects of having an ε2 allele (vs none) on longitudinal cognitive domain z scores by treatment group (chemotherapy with or without hormonal therapy, hormonal therapy, and control) controlling for covariates; participants with ε2/ε4 genotype were excluded. Sensitivity analyses examined effects of other covariates and any ε4 positivity. Results: There was an interaction with genotype for attention, processing speed, and executive functioning domain scores (Beta = 0.32, 95% confidence interval = 0.00 to 0.65); the chemotherapy group with an ε2 allele had higher scores at baseline and maintained higher scores over time compared with those without an ε2 allele, and this protective effect was not seen for other groups. There was no effect of ε2 on learning and memory domain scores. Conclusions: APOE ε2 polymorphisms may protect against CRCD in older breast cancer survivors receiving chemotherapy. With replication, this information could be useful for survivorship care and informing future studies of possible links to AD and defining mechanisms of protection.
Authors: Anna M Bennet; Emanuele Di Angelantonio; Zheng Ye; Frances Wensley; Anette Dahlin; Anders Ahlbom; Bernard Keavney; Rory Collins; Björn Wiman; Ulf de Faire; John Danesh Journal: JAMA Date: 2007-09-19 Impact factor: 56.272
Authors: Denise D Correa; Jaya Satagopan; Raymond E Baser; Kenneth Cheung; Elizabeth Richards; Michael Lin; Sasan Karimi; John Lyo; Lisa M DeAngelis; Irene Orlow Journal: Neurology Date: 2014-06-18 Impact factor: 9.910
Authors: Jeanne S Mandelblatt; Robert A Stern; Gheorghe Luta; Meghan McGuckin; Jonathan D Clapp; Arti Hurria; Paul B Jacobsen; Leigh Anne Faul; Claudine Isaacs; Neelima Denduluri; Brandon Gavett; Tiffany A Traina; Patricia Johnson; Rebecca A Silliman; R Scott Turner; Darlene Howard; John W Van Meter; Andrew Saykin; Tim Ahles Journal: J Clin Oncol Date: 2014-05-19 Impact factor: 44.544
Authors: Jeanne S Mandelblatt; Brent J Small; Gheorghe Luta; Arti Hurria; Heather Jim; Brenna C McDonald; Deena Graham; Xingtao Zhou; Jonathan Clapp; Wanting Zhai; Elizabeth Breen; Judith E Carroll; Neelima Denduluri; Asma Dilawari; Martine Extermann; Claudine Isaacs; Paul B Jacobsen; Lindsay C Kobayashi; Kelly Holohan Nudelman; James Root; Robert A Stern; Danielle Tometich; Raymond Turner; John W VanMeter; Andrew J Saykin; Tim Ahles Journal: J Clin Oncol Date: 2018-10-03 Impact factor: 44.544
Authors: Thais Minett; John Classey; Fiona E Matthews; Marie Fahrenhold; Mariko Taga; Carol Brayne; Paul G Ince; James A R Nicoll; Delphine Boche Journal: J Neuroinflammation Date: 2016-06-02 Impact factor: 8.322
Authors: Jeanne S Mandelblatt; Tim A Ahles; James C Root; Xingtao Zhou; Jaeil Ahn; Brent J Small; Wanting Zhai; Traci Bethea; Judith E Carroll; Harvey Jay Cohen; Asma Dilawari; Martine Extermann; Deena Graham; Claudine Isaacs; Paul B Jacobsen; Heather Jim; Brenna C McDonald; Zev M Nakamura; Sunita K Patel; Kelly Rentscher; Andrew J Saykin; Kathleen Van Dyk Journal: Breast Cancer Res Treat Date: 2022-05-19 Impact factor: 4.624